In the few short years since biologic agents were introduced for treating
rheumatoid arthritis, the drugs have sparked interest among clinicians and
patients because of their purported superiority to standard therapies in delaying
or preventing the deformity and disability associated with this condition.
But not everyone is convinced that the availability of these agents in the
treatment of this chronic and often debilitating disease is an unmixed blessing.
While initial studies demonstrated that patients with rheumatoid arthritis
who took biologic agents had decreased symptoms compared with those receiving
standard therapy, safety of the drugs remains a concern, along with cost .
Pressman Lovinger S. Use of Biologics for Rheumatoid Arthritis Tempered by Concerns Over Safety, Cost. JAMA. 2003;289(24):3229-3230. doi:10.1001/jama.289.24.3229